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reating Heart Failure
n Dialysis
inally Getting Some Evidence*
lke Sipahi, MD, James C. Fang, MD
leveland, Ohio
ailing of the heart and kidneys concurrently is a common
linical situation. Heart failure (HF) causing renal failure
hrough various mechanisms has been labeled as the “car-
iorenal syndrome,” and the opposite (i.e., kidney failure
ausing HF) has been recently referred to as the “renocar-
iac syndrome” (1). Among chronic renal failure patients
tarting dialysis therapy, 36% have HF, and an additional
% develop HF while receiving dialysis (2). Given that
pproximately 355,000 patients undergo long-term dialysis
n the U.S. (93% in the form of hemodialysis), it can be
stimated that in this country alone there are currently more
han 140,000 patients receiving hemodialysis with concur-
ent HF (3).
See page 1701
The risk of death while receiving hemodialysis is roughly
oubled in patients with concomitant HF. In such patients
he mean survival while receiving dialysis falls from 5.4 to
.0 years (4). Unfortunately, the treatment of this dual
rgan failure syndrome is a very challenging task. Most HF
herapies are used at low rates in HF patients receiving
ialysis. Importantly, there is little evidence from clinical
rials to support the use of proven treatment strategies
beta-blockers, renin-angiotensin-aldosterone inhibitors,
evice therapies) in hemodialysis patients, because all major
F trials have systematically excluded patients with end-
tage renal disease. Expert opinion calls for the treatment of
F in the hemodialysis setting with conventional therapies
5), despite different pathophysiologic aspects of the disease,
ltered drug and electrolyte metabolism, and lack of clinical
rial data (6).
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Harrington-McLaughlin Heart and Vascular Institute, University Hos-
itals Case Medical Center, Case Western Reserve University School of Medicine,
leveland, Ohio. Dr. Sipahi has received an educational grant and lecture honorariai
rom Pfizer, and lecture honoraria from Ranbaxy and AstraZeneca. Dr. Fang serves
n an advisory panel for Novartis.In this issue of the Journal, Cice et al. (7)—who have
reviously conducted 2 clinical trials of beta-blockers in
emodialysis patients with HF (8,9)—report a randomized
linical trial of angiotensin-receptor blocker (ARB) treat-
ent added on top of background angiotensin-converting
nzyme (ACE) inhibitor therapy in a similar patient pop-
lation. Between 1999 and 2003, they randomized 332
emodialysis patients with New York Heart Association
unctional class II to III (65% class II) HF with ejection
raction 40% to double-blind telmisartan or placebo for 3
ears. A “run-in” phase was used to assess tolerability of
ow-dose telmisartan, and after the run-in phase the agent
as titrated to the target dose of 80 mg/day every 2 weeks.
he average age was 63 years, and nearly all of them (90%)
ere men. Slightly more than one-half (57%) had a history
f myocardial infarction. All patients were taking an ACE
nhibitor at baseline, approximately 60% of them were
aking beta-blockers, two-thirds were taking statins, and
pproximately one-half were receiving digitalis. None of the
atients had cardiac resynchronization therapy or an im-
lantable cardioverter-defibrillator. Predictably, there was a
igh background rate of all-cause mortality (1 of the 3
rimary end points) in the placebo group (i.e., 54% at 3
ears). The hazard ratio (HR) for all-cause death in the
elmisartan group was a striking 0.51 (95% confidence
nterval: 0.32 to 0.82, p  0.01). The hazard for the other
rimary end points of cardiovascular death (HR: 0.42, p 
.0001) and HF hospital stay (HR: 0.38, p  0.0001) were
lso greatly reduced. These benefits were seen early (3
onths), and the decrease in mortality was driven by
eductions in pump failure, sudden deaths, and “non-
ardiovascular” causes of death; there were few myocardial
nfarctions or strokes overall. Serial echocardiographic data
lso paralleled the clinical outcomes in that there was more
eft ventricular (LV) reverse remodeling (e.g., improved
jection fraction and decreased end-diastolic dimension) in
he telmisartan group, which was noted by 6 months and
ontinued up to 2 years.
Telmisartan was well-tolerated for the most part, even
hough full-dose telmisartan was force titrated in addi-
ion to full-dose ACE inhibitor (and in most cases, a
asodilating beta-blocker) with a baseline pre-dialytic
lood pressure of 125/84 mm Hg. Only 19 patients
5.4%) were excluded after the run-in phase, of which
nly 7 were due to hypotension. However, there were
ore permanent treatment withdrawals (26 vs. 16) in the
elmisartan group. Adverse events leading to study drug
iscontinuation were surprisingly uncommon for a clin-
cal drug trial (16.3% vs. 10.7%). As anticipated, the most
ommon adverse event was hypotension (as is observed
requently in hemodialysis patients with HF), which was
ignificantly more common with telmisartan (67% vs.
0%), particularly in those who were taking both ACE
nhibitors and beta-blockers. Hyperkalemia, although
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Treating HF on Dialysis November 16, 2010:1709–11are overall, was also more common with telmisartan (3%
s. 1%).
The striking benefits of this apparently well-tolerated
herapy in a nonhypertensive patient cohort certainly make
ne wonder as to the mechanism. In systolic HF without
dvanced renal insufficiency, early studies using surrogate
nd points such as blood pressure and LV remodeling
rovided a strong rationale as well as safety data for the
ddition of an ARB to an ACE inhibitor. However, the
linical benefits were quite modest in the subsequent large-
cale clinical trials. Although the mechanisms of benefit
ith telmisartan observed in this study are not entirely clear,
t could include the effects of neurohormonal antagonism
esulting in reverse remodeling as shown in the echocardio-
raphic analysis of this trial. Angiotensin-receptor blockers
uch as telmisartan might be more effective renin-
ngiotensin system (RAS) antagonists in this patient pop-
lation, because ACE inhibitors are in large part removed
y dialysis, their dosing is derived from non-dialysis popu-
ations, and their effectiveness in decreasing LV mass in this
roup of patients is unclear (10). In fact, there are no
arge-scale clinical trials of ACE inhibitors in dialysis
atients that demonstrate clinical benefit. A hemodynamic
ffect could also be relevant in that the clinical benefits seem
o accrue early and before LV remodeling would be expected
o be seen. The hemodynamic effect might be primarily
ue to improvements in vascular stiffness rather than blood
ressure lowering alone. Aortic pulse wave velocity is an
ndependent predictor of survival in dialysis-dependent
enal failure, and blood pressure lowering might only be of
enefit if pulse wave velocity is concomitantly lowered (11).
inally, effective RAS antagonism might also decrease
rrhythmic risk and has been noted in trials of both ARBs
nd ACE inhibitors.
Or are these results too good to be true? The positive
redictive value of clinical trials (i.e., whether a positive
linical trial is truly positive) depends on: 1) the pre-test
robability of the null hypothesis being wrong; 2) the power
f the study; and 3) bias (12). Effect size and the level of
ignificance are also important parameters in evaluating a
tudy. For estimating the pre-test probability for this study,
ajor Randomized Placebo-Controlled Trials of ARBs Added to BacTable 1 Major Randomized Placebo-Controlled Trials of ARBs A
Trial/First Author
(Ref. #) Inclusion Criteria Study Regimen
Average
Duration, yrs
Val-HeFT (13) NYHA II–IV HF,
LVEF 40%
(n 5,010)
Valsartan up to
160 mg
twice a day
1.9
CHARM-Added (14) NYHA II–IV HF,
LVEF 40%
(n 2,548)
Candesartan up
to 32 mg/day
3.4
Cice et al. (7) Hemodialysis patients
with NYHA II or III HF,
LVEF 40%
(n 332)
Telmisartan up
to 80 mg/day
3.0CE angiotensin-converting enzyme; ARB angiotensin-receptor blocker; CHARM Candesartan in Hea
ailure; HR  hazard ratio; LVEF  left ventricular ejection fraction; NA  not available; NYHA  New Yohere is little information from previous trials in hemodial-
sis patients with HF. However, data from HF patients not
eceiving hemodialysis are available, which is probably the
ost relevant information in this context (Table 1). Two
arge-scale, double-blind, placebo-randomized trials of 2
ifferent ARBs, valsartan (VaL-HeFT [Valsartan Heart
ailure Trial]) (13) and candesartan (CHARM [Candesar-
an in Heart Failure Assessment of Reduction in Mortality
nd Morbidity]-Added trial) (14), have been published.
either of these trials showed a statistically significant effect
n mortality. The pre-test probability of angiotensin-
eceptor blockade to reduce mortality in this context (i.e.
dded to an ACE inhibitor) would not be expected to be
ery high in a repeat trial, albeit in a nondialysis patient
opulation. Ioannidis (12) has shown, with regard to the
ssue of power, that insufficient power not only inflates the
ype II error rate (failing to reject null hypothesis when it is
rong) but also reduces the positive predictive value of
linical trials. Although the power calculations in the
resent study showed 90% power, this was to detect a 50%
azard reduction in death, not a commonly seen magnitude
f benefit with most agents in any clinical trial setting.
iven this aggressive target of event-reduction benefit and
modest total number of patients (which is comparable to
“pilot” trial), it is not clear whether this trial provides
nough power to be definitive. Although it is difficult to
udge the level of bias in this communication, the delay in
he publication of this trial (approximately 5 years between
tudy completion and full-text publication) is unusual.
onversely, the remarkable effect size, the robust levels of
ignificance, and the similarity of these results to 2 other
RB trials in hemodialysis patients (not necessarily with
oncomitant HF) (15,16) are important strengths of the
rial. Notably, the effect size of mortality reduction was
uch greater than the modestly increased risk of cancer
ith ARBs reported in the recent meta-analysis of random-
zed controlled trials (17).
All things considered, the findings of Cice et al. (7) are
mportant and, like all important studies, should lead to
urther investigation. Given the grim prognosis of hemo-
ialyzed patients with HF and the premise for improved
nd ACE Inhibitor Therapy in Patients With HFto Background ACE Inhibitor Therapy in Patients With HF
All-Cause Mortality Hospitalization for HF
RB Placebo HR (95% CI) ARB Placebo HR (95% CI)
.7% 19.4% 1.02 (0.88–1.18) 13.8% 18.2% NA
.5% 32.4% 0.89 (0.77–1.02) 24.2% 28.0% 0.83 (0.71–0.96)
.1% 54.4% 0.51 (0.32–0.82) 33.9% 55.1% 0.38 (0.19–0.51)kgroudded
A
19
29
35rt Failure Assessment of Reduction in Mortality and Morbidity; CI confidence interval; HF heart
rk Heart Association functional class; Val-HeFT  Valsartan Heart Failure Trial.
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November 16, 2010:1709–11 Treating HF on Dialysisongevity with aggressive RAS inhibition in the current
tudy, it would be reassuring to see another larger trial of
dd-on angiotensin-receptor blockade in this patient pop-
lation with similar findings. These investigators should be
iven credit for paving the way to providing the clinician an
vidence base from which to make relevant therapeutic
ecisions in this complex and mortal disease state. For now,
linicians should carefully evaluate the choice of agents in
he treatment of HF when it complicates dialysis and make
ure that drugs that antagonize both the RAS and adren-
rgic axes are considered.
eprint requests and correspondence: Dr. James C. Fang,
ivision of Cardiovascular Medicine, University Hospitals Case
edical Center, 11100 Euclid Avenue, LKS 5038, Cleveland,
hio 44106. E-mail: james.fang@uhhospitals.org.
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